Table of Content

1. Introduction to KRAS Inhibitors
1.1 Development of KRAS Inhibitors
1.2 Mechanism Of Action
1.3 Role of KRAS Inhibitors in Cancer Therapy


2. Lumakras – First Approved KRAS Inhibitor
2.1 Overview & Patent Insight
2.2 Dosage & Price Analysis
2.3 Sales Analysis


3. Krazati - Second Approved KRAS Inhibitor
3.1 Overview & Patent Insight
3.2 Dosage & Price Analysis
3.3 Sales Analysis


4. Global KRAS Inhibitor Market Outlook
4.1 Current Market Scenario
4.2 KRAS Inhibitors Candidates Granted Breakthrough & Orphan Designations
4.3 Future Market Opportunity


5. KRAS Inhibitor Market Regional Analysis: Commercial & Clinical Development Outlook
5.1 US
5.2 UK
5.3 China
5.4 Europe
5.5 Japan
5.6 South Korea
5.7 Canada
5.8 Taiwan
5.9 Australia



6. KRAS Inhibitor Market By Indications: Clinical Trials & Modernization Insights
6.1 Lung Cancer
6.2 Colorectal Cancer
6.3 Pancreatic Cancer
6.4 Other Indications


7. Global KRAS Inhibitors Clinical Pipeline Overview
7.1 By Country
7.2 By Phase
7.3 By Company
7.4 By Indication
7.5 By Patient Segment


8. Global KRAS Inhibitor Clinical Trials Insight By Country, Company, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III
8.8 Preregistration


9. Marketed KRAS Inhibitor Clinical Trials Insight By Country, Company & Indication


10. Combination Strategies with KRAS Inhibitors
10.1 Immunotherapy
10.2 Oncolytic Virus Immunotherapy
10.3 Chemotherapy
10.4 Targeted Therapies


11. Global KRAS Inhibitors Market Dynamics
11.1 Market Drivers
11.2 Market Challenges


12. Competitive Landscape
12.1 Array BioPharma (Pfizer)
12.2 Applied Pharmaceutical Science
12.3 Amgen
12.4 AnBogen Therapeutics
12.5 Ascentage Pharma
12.6 AstraZeneca
12.7 Biond Biologics
12.8 BridgeBio Pharma
12.9 Bristol Myers Squibb
12.10 Boehringer Ingelheim
12.11 Carmot Therapeutics (Roche)
12.12 Eli Lilly
12.13 Erasca
12.14 FogPharma
12.15 Frontier Medicines
12.16 Jacobio Pharmaceuticals
12.17 Jemincare
12.18 Jiangsu Hansoh Pharmaceutical
12.19 Jiangsu Hengrui Medicine Co.
12.20 Loxo Oncology (Eli Lilly)
12.21 Mirati Therapeutics
12.22 Quanta Therapeutics
12.23 REVOLUTION Medicines
12.24 Roche
12.25 Suzhou Genhouse Bio
12.26 Suzhou Zelgen Biopharmaceuticals



List of Tables

Table 2 1: Recommended Lumakras Dosage Modifications for Adverse Reactions

Table 3 1: Recommended Krazati Dosage Modifications for Adverse Reactions

Table 4 1 KRAS inhibitors Granted Designations

Table 5-1: UK - Ongoing Clinical Trials for KRAS Inhibitors
Table 5-2: China – Some KRAS inhibitors in Ongoing Clinical trials
Table 5-3: Japan –Ongoing Clinical Trials for KRAS inhibitor as Monotherapy
Table 5-4: Japan –Ongoing Clinical Trials for KRAS inhibitor as Combination Therapies
Table 5-5: South Korea - Ongoing Clinical Trials for KRAS Inhibitors
Table 5-6: Canada - Ongoing Clinical Trials for KRAS Inhibitors
Table 5-7: Taiwan - Ongoing Clinical Trials for KRAS Inhibitors
Table 5-8: Australia - Ongoing Clinical Trials for KRAS Inhibitors

Table 6-1: Colorectal Cancer – KRAS Inhibitors in Clinical Trials
Table 6-2: Colorectal Cancer – KRAS Inhibitors with Regulatory Designations
Table 6-3: Pancreatic Cancer – KRAS Inhibitors in Clinical Trials
Table 6-4: Pancreatic Cancer – KRAS Inhibitors with Regulatory Designations